Aquestive Therapeutics, Inc. (AQST)
NASDAQ: AQST · Real-Time Price · USD
4.390
-0.075 (-1.68%)
At close: Jun 26, 2026, 4:00 PM EDT
4.400
+0.010 (0.23%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Aquestive Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Aquestive Therapeutics stock have an average target of 8.75, with a low estimate of 6.00 and a high estimate of 11. The average target predicts an increase of 99.32% from the current stock price of 4.39.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aquestive Therapeutics stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 2 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $11 | Buy | Maintains | $11 | +150.57% | Jun 26, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $9 | Buy | Reiterates | $9 | +105.01% | Jun 25, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 | Buy | Reiterates | $8 | +82.23% | Jun 25, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $9 | Buy | Reiterates | $9 | +105.01% | May 15, 2026 |
| Lake Street | Lake Street | Buy Maintains $6 | Buy | Maintains | $6 | +36.67% | May 15, 2026 |
Financial Forecast
Revenue This Year
50.51M
from 44.55M
Increased by 13.40%
Revenue Next Year
71.92M
from 50.51M
Increased by 42.38%
EPS This Year
-0.42
from -0.59
EPS Next Year
-0.45
from -0.42
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 55.3M | 112.0M | |
| Avg | 50.5M | 71.9M | |
| Low | 47.4M | 52.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 24.1% | 121.7% | |
| Avg | 13.4% | 42.4% | |
| Low | 6.5% | 3.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -0.36 | -0.45 | |
| Avg | -0.42 | -0.45 | |
| Low | -0.48 | -0.45 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.